Osteoclasts are active in bone forming metastases of prostate cancer patients

PLoS ONE

Volumn 3, Issue 11, 2008, Pages

  Roato, Ilaria ^a   D'Amelio, Patrizia ^a   Gorassini, Eva ^a   Grimaldi, Anastasia ^a   Bonello, Lisa ^a   Fiori, Cristian ^a   Delsedime, Luisa ^a   Tizzani, Alessandro ^a   De Libero, Alfredo ^a   Isaia, Giancarlo ^a   Ferracini, Riccardo ^a  

^a University and AZO San Giovanni Battista   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 7; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; DKK1 PROTEIN, HUMAN; IL7 PROTEIN, HUMAN; OSTEOPROTEGERIN; SIGNAL PEPTIDE; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE DEVELOPMENT; BONE METABOLISM; BONE METASTASIS; CELL ACTIVITY; CELL CULTURE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OSTEOCLAST; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; URINALYSIS; BLOOD; BONE REMODELING; BONE TUMOR; CARCINOMA; CASE CONTROL STUDY; CELL DIFFERENTIATION; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; OSTEOLYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

AGED; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; CARCINOMA; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-7; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS; RANK LIGAND;

EID: 56149084790     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003627     Document Type: Article

References (31)

1. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, et al. (2001) Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 20: 333-349.
2. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, et al. (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31: 578-583.
3. Logothetis CJ, Lin SH (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5: 21-28.
4. Roato I, Brunetti G, Gorassini E, Grano M, Colucci S, et al. (2006) IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS ONE 1: e124.
5. Zhang J, Dai J, Qi Y, Lin DL, Smith P, et al. (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107: 1235-1244.
6. Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, et al. (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8: 751-764.
7. Morvan F, Boulukos K, Clement-Lacroix P, Roman Roman S, Suc-Royer I, et al. (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21: 934-945.
8. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, et al. (2008) Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27: 596-603.
9. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494.
10. Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91: 718-729.
11. Jacobs SC (1983) Spread of prostatic cancer to bone. Urology 21: 337-344.
12. Schwartz GG (2008) Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev 17: 478-483.
13. Roato I, Grano M, Brunetti G, Colucci S, Mussa A, et al. (2005) Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. Faseb J 19: 228-230.
14. Lau YS, Adamopoulos IE, Sabokbar A, Giele H, Gibbons CL, et al. (2007) Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. Br J Cancer 96: 1716-1722.
15. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, et al. (2005) Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65: 1710-1718.
16. Al-Rawi MA, Mansel RE, Jiang WG (2003) Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours. Histol Histopathol 18: 911-923.
17. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, et al. (2005) Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106: 2472-2483.
18. Roato I, Gorassini E, Buffoni L, Lyberis P, Ruffini E, et al. (2007) Spontaneous osteoclastogenesis is a predictive factor for bone metastases from non-small cell lung cancer. Lung Cancer.
19. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, et al. (2007) Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol 212: 47-55.
20. D'Amelio P, Grimaldi A, Bernabei P, Pescarmona GP, Isaia G (2006) Immune system and bone metabolism: Does thymectomy influence postmenopausal bone loss in humans? Bone 39: 658-665.
21. Emami KH, Corey E (2007) When prostate cancer meets bone: control by wnts. Cancer Lett 253: 170-179.
22. Levasseur R, Lacombe D, de Vernejoul MC (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72: 207-214.
23. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, et al. (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97: 964-970.
24. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET (2005) Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65: 7554-7560.
25. D'Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, et al. (2008) Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 43: 92-100.
26. Brown JE, Cook RJ, Major P, Lipton A, Saad F, et al. (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59-69.
27. Mancini I, Dumon JC, Body JJ (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22: 3587-3592.
28. Ebert W, Muley T, Herb KP, Schmidt-Gayk H (2004) Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24: 3193-3201.
29. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, et al. (2001) Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47: 597-600.
30. Killian CS, Chu TM (1990) Prostate-specific antigen: questions often asked. Cancer Invest 8: 27-37.
31. Gleason D (1977) Urologic Pathology: The Prostate. MT, ed. Philadelphia: Lea and Febiger. pp 171-198.